WO2015145054A2

WO2015145054A2 - Implantable biocompatible reactor

Info

Publication number: WO2015145054A2
Application number: PCT/FR2015/050725
Authority: WO
Inventors: Sarra EL ICHI; Donald K. MARTIN; Philippe Cinquin; Abdelkader Zebda
Original assignee: Universite Joseph Fourier
Priority date: 2014-03-25
Filing date: 2015-03-23
Publication date: 2015-10-01
Also published as: EP3123544A2; EP3123544B1; CA2943392C; FR3019384A1; WO2015145054A3; FR3019384B1; CA2943392A1; US10316284B2; US20170081626A1

Abstract

The invention concerns a bioreactor obtained by compressing a mixture of an enzyme, a conductor and chitosan. The conductor can consist of carbon nanotubes. This bioreactor can be produced according to the following steps: preparing a mixture of powders in which the proportion of enzyme powder relative to a carbon nanotube powder is of the order of 50/50 by weight; preparing a viscous solution of chitosan in a ratio of 5 to 15 (in mg) of chitosan to 0.75 to 1.25 (in ml) of acetic acid diluted to 0.4 to 0.6 % by volume in water; adding the viscous chitosan to the mixture of powders in a proportion be weight of 3 to 5 of powder to 5 to 10 of chitosan; carrying out a first compression followed by light grinding; carrying out a second compression to produce a pellet; and drying at ambient temperature.

Description

IMPLANTABLE BIOCCMPATIBLE REACTOR

The present patent application claims the priority of the French patent application FR14 / 52534 which will be considered as an integral part of the present description.

Field

The present invention relates to an implantable reactor in vivo, at which a reaction between elements confined in this reactor and compounds present in the host organism is likely to occur. This reaction may for example lead to a deformation of the reactor, to the generation of an electrical potential, or to the chemical transformation of the compound interacting with the reactor.

A reactor leading to the generation of an electric potential may constitute an electrode of a biopile or a biosensor, of the sugar-oxygen type, for example glucose-oxygen.

A reactor leading to the chemical transformation of a compound interacting with the reactor will for example constitute a glucose killer, for example by transforming glucose into a compound that will be eliminated by the body.

Although the invention and the state of the art are described here mainly in the case of bioelectrodes of a biopile, it will be understood that the invention applies generally to any implantable reactor in vivo.

Presentation of the prior art

Various types of glucose-oxygen biopiles are described in the prior art, for example in patent application PCT / FR2009 / 050639 (B8606). In these known biopiles, each electrode, anode and cathode, corresponds to an enclosure containing a liquid medium in which a wire élec ^¬ trode. The anode and cathode enclosures are delimited by membranes which can be traversed by hydrogen and oxy ^¬ gene but avoiding traffic other heavier elements.

The anode comprises in a solution an enzyme and a redox mediator. The enzyme is capable of catalyzing the oxidation of sugar and is for example selected from the group comprising glucose oxidase if the sugar is glucose and lactose oxidase if the sugar is lactose. The redox mediator has a low redox potential capable of exchanging electrons with the anode enzyme and is for example selected from the group comprising: ubiquinone (UQ) and ferrocene.

The cathode also comprises in a solution an enzyme and preferably a redox mediator. The enzyme is capable of catalyzing the reduction of oxygen and is for example selected from the group comprising: polyphenol oxidase (PPO), laccase and bilirubin oxidase. The redox mediator has a high redox potential capable of exchanging electrons with the cathode enzyme and is for example chosen from the group comprising: hydroquinone (QH2) and 2,2'-azinobis- (3-ethylbenzo-thiazoline-6) -sulfonate) (ABTS).

At the level of the anode and the cathode, reactions of the following type occur:

OPP

Cathode: QH ₂ + 1/2 0 ₂ Q + H ₂ 0

GOX

Anode: glucose + UQ gluconolactone + UQH2

Cathode: Q + 2H + + 2e ^~ → QH ₂

Anode: UQH ₂ → UQ + 2H + + 2e ^~ these reactions being given in the particular case where the sugar is glucose, the anode enzyme is glucose oxidase (GOX), the redox anode mediator is ubiquinone (UQ), the enzyme of cathode is polyphenol oxidase (PPO), and the redox cathode mediator is quinhydrone (() ¾). An anode potential of 20 mV and a cathode potential of 250 mV are then obtained, which leads to a zero current potential difference of the 230 mV biopile.

Such biopiles work well but, particularly with regard to the biopile described in patent application PCT / FR2009 / 050639, require that anode conductors and cathode dip in enclosures containing appropriate liquids, which is a drawback practice in many cases and makes it particularly difficult if not impossible to implant such biopiles in a living being.

Indeed, one seeks to implant such biopiles in living beings, in particular to feed various actuators, such as pacemakers, artificial sphincters, or even artificial hearts.

Solid electrode biopiles have been proposed.

However, biopiles using such electrodes, especially when they are implanted in a living being, have had a short life.

An oxygen glucose biopile implantable in vivo is described in particular in the European patent EP 2,375,481 of the Applicant (B10272). The contents of this patent will be considered here as known and as an integral part of the present description.

In this patent, it is proposed to manufacture anode and cathode pellets of a biopile from a compression of a conductor such as graphite and an enzyme to which is added a redox mediator. The cathode and the anode, and preferably all of the anode and the cathode, are surrounded by a semi-permeable enclosure, for example of the type used in dialysis, to pass glucose and oxygen. and do not let enzymes and redox mediators pass. The conductive material from which are made the compres sion ^¬ anode and the cathode of compression is indicated as graphite or a conductive polymer.

Figure 1 below reproduces Figure 2 of this prior patent. It shows an anode pellet A and a cathode pellet K integral respectively conductors 1 and 3. The anode is surrounded by a semipermeable membrane 11, the cathode of a semipermeable membrane 12 and the together is surrounded by a semi-permeable membrane 13.

Satisfactory in vivo experimental results have been obtained with the biopile electrodes described in this patent.

However, it is desirable to further improve the lifetime of the electrodes, that is to say the operating time of the biopile and to maximize the biocompatibility of this battery.

More generally, it is desirable to improve the life of bioreactors as defined above.

summary

Thus, a bioreactor obtained by compression of a mixture of an enzyme, a conductor and chitosan is provided.

According to one embodiment, the conductor consists of carbon nanotubes.

There is also provided a method of manufacturing a bioreactor comprising the following steps:

preparing a mixture of powders in which the proportion of enzyme powder relative to a carbon nanotube powder is of the order of 50/50 by weight;

prepare a viscous solution of chitosan in a ratio of 5 to 15 (in mg) of 0.75 to 1.25 chitosan (in ml) of acetic acid diluted to 0.4 to 0.6% by volume in water; add to the powder mixture the viscous chitosan in a weight ratio of 3 to 5 for the powder at 5 to 10 for chitosan;

make a first compression then a light grinding;

perform a second compression to make a pellet; and

dry at room temperature.

According to one embodiment, the pressure applied during the first and second compression is in a range of 2000 to 6000 kPa.

According to one embodiment, the solution comprises from 0.002 to 0.005% by weight per volume of genipin.

According to one embodiment, the solution comprises from 0.001 to 0.005% by weight per volume of caffeic acid.

A bioreactor is also provided in which a porous membrane based on chitosan is placed on the active face and adhered to the periphery thereof.

According to one embodiment, the bioreactor is a lozenge-shaped bioelectrode in which a conductor is bonded via a conductive adhesive to the face of the tablet opposite to the active face.

According to one embodiment, the membrane comprises pores with an average diameter of the order of 1 to 10 nanometers.

According to one embodiment, the membrane comprises a smooth face facing the pellet and a rough face facing outwards.

There is also provided a method of manufacturing a porous membrane for a bioreactor, comprising the steps of:

prepare a solution in a ratio of 5 to 15 (in mg) of 0.75 to 1.25 chitosan (in ml) of acetic acid diluted to 0.4 to 0.6% in water;

shake ;

pour on a smooth support; and dry for 2 to 4 days at room temperature.

Brief description of the drawings

These and other features and advantages will be set forth in detail in the following description of particular embodiments in a non-limiting manner with reference to the accompanying drawings in which:

Figure 1 corresponds to Figure 2 of European Patent EP 2 375 481;

Figures 2A and 2B are respectively a sectional view and a top view of an embodiment of an electrode; and

FIG. 3 represents current characteristics as a function of time of various biopiles.

detailed description

First of all, it is intended here to manufacture a bioelectrode tablet not from the compression of only one conductor and an enzyme, but from a compression of chitosan, an enzyme and a conductor and possibly a redox mediator and other additives. The conductor may advantageously consist of multiwall carbon nanotubes (MWCNT - MultiWalled Carbon NanoTubes).

A mixture of powders of an enzyme and of carbon nanotubes is initially prepared, the proportion of enzyme powder relative to the carbon nanotube powder being of the order of 50/50 by weight, this proportion possibly varying approximately 20%.

A viscous chitosan solution is also prepared by adding chitosan powder in acetic acid diluted to 0.5 volume%, heated to 50 ° C, and stirring for 2 hours at room temperature.

The viscous chitosan is added to the powder mixture in a weight ratio of 2 for the powder to 3 for chitosan. For a pellet, for example, 0.04 gram of powder and 0.06 gram of chitosan will be used. A mixture of the powder and the chitosan in the viscous state is made and a first compression is carried out and then a light grinding. A second compression is then performed, which, like the first compression, is carried out at a pressure selected in the range of 2000 to 6000 kPa to provide a pellet, followed by drying for two to four days at room temperature (20 ° C). 30 ° C) so that the whole polymerizes.

It is possible to add to the initial mixture a crosslinking agent, for example genipin at 0.0045% by weight per volume (g / 100 ml) in the viscous solution of chitosan after 2 hours of stirring. The genipin is first solubilized in a solution of 12% dimethylsulfoxide (DMSO) and 88% water (H ₂ O). It is also possible to improve the acidic membrane resistance by adding to the initial mixture a product such as caffeic acid in a proportion of 0.0032% by weight per volume (g / 100 ml) in the viscous chitosan solution. The caffeic acid is previously solubilized at 4% in ethanol. The solution is allowed to stir for 30 min before taking 3 g to spread on the smooth support for drying as previously described.

A feature of the process described herein is that during the second compression and drying, the chitosan is made into interconnected long fibers with a diameter of about 30 nm. It will be emphasized that a three-dimensional nanofibrous and nanoporous network is obtained simply by compression of the polymer with the powder and evaporation of the solvent at room temperature. As a result, the enzyme and carbon nanotubes are immobilized in the chitosan fiber matrix and do not migrate out of the pellet.

This has a significant advantage because the enzyme, trapped by the fiber matrix, remains protected and active for a long time. In addition, it is necessary to trap carbon nanotubes, questions currently posed on the possible harmfulness of carbon nanotubes in vivo. A biocathode comprising only a conductor and an enzyme, as described in the aforementioned prior patent, has a 1-month stability in batch operation. A biocathode based on chitosan-MWCNT-laccase, as described herein, has a stability greater than 2 months in continuous operation. In vitro measurements show that the discontinuous operation stability of the biocathode described here exceeds six months. In addition, this stability is also ensured in vivo for a period greater than 200 days. This demonstrates that the bioelectrode described here provides the enzyme with a protective environment for its activity but also retains the enzyme within the electrode pellet and near the carbon nanotubes for electrical conduction. The porosity of the three-dimensional matrix of chitosan allows a good diffusion of the substrates of the enzyme.

As an alternative, instead of using carbon nanotubes, graphene, gold powder or a conductive polymer such as polyaniline can be used as the conductor.

Particular embodiments have been described.

Various variations and modifications will be apparent to those skilled in the art. In particular, the polymer may be chitosan or other biocompatible polymer, for example: polyvinyl alcohol, poly (methylmethacrylate), gelatin, dextran, or copolymers such as chitosan-polyethylene glycol or a mixture of these polymers.

The method of manufacturing conductive polymer and enzyme electrodes can be applied to the cathode or the anode. Different enzymes can be immobilized in this structure: laccase, bilirubin oxidase, polyphenol oxidase, glucose oxidase, glucose dehydrogenase, catalase, peroxidase.

According to another aspect of the present invention, there is provided a particular filter membrane for an enzymatic bioelectrode as above or any other enzymatic bioelectrode obtained by compression of a conductor, an enzyme and optionally a redox mediator - the redox mediator is not indispensable in the cathode.

As illustrated in FIGS. 2A and 2B, the electrode is in the form of a tablet 20 having for example a circular shape in plan view, a diameter of 0.5 to 1 cm and a thickness of 0.5 to 2 mm. On the lower face of the wafer 20 is fixed a conductive strip 22 for example by a conductive adhesive, for example a carbon paste 24 itself coated with a protective layer of silicone adhesive 25, selected from biocompatible glues. On the upper face of the pellet 20 is placed - and not deposited - a membrane 26 bonded at its periphery to the pellet by a ring of silicone glue 28.

It is intended here to use for membrane 26 a membrane based on chitosan. This membrane is for example obtained starting from a solution in a ratio of 5 to 15, for example 10 (in mg) of chitosan at 0.75 to 1.25, for example 1 (in ml) of diluted acetic acid. 0.4 to 0.6% by volume in water and heated to 50 ° C. In one test, 200 mg of chitosan were dissolved in 20 ml of acetic acid diluted to 0.5% by volume in water. This mixture is stirred for two hours. Then, 3 g of this mixture were taken and spread on a non-adhesive smooth support (diameter 28 cm), for example an antistatic polystyrene cup, and dried for 2 to 4 days at room temperature, by example at a temperature of 20 to 30 ° C. In one test, it was dried for three days at 25 ° C.

A flexible nanoporous film is thus obtained. Experiments carried out by the applicant have shown that this flexibility is related to the fact that the drying is carried out for a long time at ambient temperature. This characteristic is not obtained for example if drying temperatures above 40 ° C are used. For a film thickness of the order of 7 to 15 μm, for example 10 μm, obtained a porous membrane with average pore diameters of the order of 1 to 10 nanometers. It is preferable to place oneself in conditions where this average diameter is of the order of 5 to 8 nm in order to allow the glucose to pass and to filter the compounds of larger dimensions.

As in the context of making a pellet, it may be added to the initial mixture a crosslinking agent, for example genipin, and an acid-resistant agent, for example caffeic acid.

The film obtained has a difference in roughness between the two faces which is due to the fact that one of the faces (the rougher) has been in contact with the air and not the support (smooth side). During assembly, the rough surface will preferably be placed outwards with respect to the surface of the bioelectrode pellet. Indeed, the difference in roughness on a thin film influences the ion diffusion and consequently the electrical resistivity. The inventors have shown that the chitosan film has good ionic conductivity (10 ^{~ 4} S. cm ^-1 ). This ionic conductivity is better than that obtained with commercial membranes such as Nation or cellulose acetate.

The chitosan film described here makes it possible, by virtue of its mechanical properties, in particular its flexibility and its adequate degree of swelling, to confer a mechanical stability on the electrode by marrying the surface of the pellet after swelling thereof in the liquid. It confers a biocompatible interface to the tissue contact after implantation of the biopile. It constitutes an effective barrier against a possible release of the constituents of the electrode on the one hand, and against the biological molecules coming from the extracellular liquid.

The pore diameter can be adjusted by modifying: the concentration of the chitosan in the solvent (acetic acid), the ratio chitosan / crosslinking agent, the molecular weight of the chitosan powder placed in the initial solution of acetic acid. Figure 3 shows a current characteristic in mA / ml (the milliliters corresponding to the volume of the pellet) as a function of time in days for various biopiles. Curve A corresponds to the case where a cellulose acetate membrane was used, curve B in the case where a Nation membrane was used, and curve C in the case where a chitosan-based membrane was used such that previously described. It can be seen that the (negative) current is much larger in the case of the chitosan membrane and that the characteristics of the biocell do not degrade, quite the opposite, as a function of time. On the other hand, it is noted that for cellulose acetate, the characteristic starts from a value of -0.15 and falls to a value of about -0.05 after about 70 days. With a membrane in Nation, a relatively constant characteristic is obtained but current densities two to three times lower than with a membrane based on chitosan.

Although the invention and the state of the art are described here mainly in the case of a bioelectrode, it will be understood that the invention applies generally to any implantable bioreactor in vivo, as defined at the beginning of the this description.

Claims

1. Bioreactor obtained by compression of a mixture of an enzyme, a conductor and chitosan.

2. Bioreactor according to claim 1, wherein the conductor consists of carbon nanotubes.

3. A method of manufacturing a bioreactor according to claim 1 or 2, comprising the following steps:

prepare a viscous solution of chitosan in a ratio of 5 to 15 (in mg) of 0.75 to 1.25 chitosan (in ml) of acetic acid diluted to 0.4 to 0.6% by volume in water;

add to the powder mixture the viscous chitosan in a weight ratio of 3 to 5 for the powder at 5 to 10 for chitosan;

make a first compression then a light grinding;

perform a second compression to make a pellet; and

dry at room temperature.

The method of claim 3, wherein the pressure applied during the first and second compression is in the range of 2000 to 6000 kPa.

The method of claim 3 or 4, wherein the solution comprises from 0.002 to 0.005 wt.% By volume of genipin.

6. A process according to claim 3 or 4, wherein the solution comprises from 0.001 to 0.005% by weight per volume of caffeic acid.

7. Bioreactor according to claim 1 or 2, wherein a porous membrane (26) based on chitosan is placed on an active side of the bioreactor and bonded to the periphery thereof.

8. Bioreactor according to claim 7 constituting a lozenge-shaped bioelectrode (20), in which a conductor (22) is bonded via a conductive adhesive (24) to the face of the tablet opposite to the active face. .

9. Bioreactor according to claim 7 or 8, wherein the membrane comprises pores with an average diameter of the order of 1 to 10 nanometers.

10. Bioreactor according to any one of revendi ^¬ cations 7 to 9, wherein the membrane comprises a smooth face facing the pellet and a rough face facing outwardly.

11. A method of manufacturing a porous membrane for a bioreactor according to any one of claims 7 to 9, comprising the following steps:

shake ;

pour on a smooth support; and

dry for 2 to 4 days at room temperature.